Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Novavax (NVV1) Stock Price & Analysis

9 Followers

NVV1 Stock Chart & Stats

€9.20-€0.52(-3.26%)
At close: 5:30 PM GMT+1
€7.5€10Aug 17Aug 31Sep 14Sep 28Oct 12Oct 27Nov 9
Day’s Range
EUR 9.20 - EUR 9.72
52-Week Range
EUR 5.44 - EUR 11.84
Previous Close
EUR 9.51
Volume
N/A
Average Volume (3M)
2,566
Market Cap
EUR 1.51B
Enterprise Value
EUR 1.46B
Total Cash (Recent Filing)
EUR 622.36M
Total Debt (Recent Filing)
EUR 292.09M
Price to Earnings (P/E)
―
Beta
1.52
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
0.49
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sanofi Partnership Monetization

The Sanofi relationship provides validated commercial access, significant milestone economics, and potential future royalties. Phase III progress and additional technology-transfer and launch milestones create a durable partner-backed revenue stream beyond standalone COVID vaccine sales.

Matrix-M Platform Validation

Matrix-M has moved beyond a single-product concept into multiple commercial vaccine applications, including malaria. Broad partner interest and commercial validation can support licensing, adjuvant supply revenue, and future applications across infectious-disease programs.

Cost Structure And Liquidity Plan

Planned reductions in R&D, SG&A, headcount, and operating footprint could materially lower the break-even base. Combined with stated cash runway into 2029 and planned liability repayment, this improves financial flexibility while the pipeline and partnerships mature.

Bears Say

Revenue And Profitability Volatility

The sharp reversal from annual growth and profitability to declining TTM revenue and losses indicates limited earnings durability. Revenue normalization and an insufficient operating scale make future results dependent on uneven product demand and partnership-related contributions.

Negative Shareholders’ Equity

A persistently negative equity base is a structural balance-sheet weakness that restricts financial flexibility and distorts leverage measures. It can raise funding pressure and leave fewer resources available to absorb operating setbacks or invest through extended development cycles.

Persistent Cash Burn

Negative operating and free cash flow show that the business is not yet self-funding, despite relatively attractive gross margins. Continued cash outflows increase dependence on existing liquidity, milestones, partnerships, or future commercialization to support operations.

Novavax News

NVV1 FAQ

What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €5.44 and its highest was €11.84 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is €1.51B.
When is Novavax’s upcoming earnings report date?
Novavax’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 112 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 05, 2026. The company reported -€0.17 earnings per share for the quarter, beating the consensus estimate of -€0.31 by €0.14.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is 0.49.
How many shares outstanding does Novavax have?
Novavax has 165,009,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.17 in its last earnings report, beating expectations of -€0.31. Following the earnings report the stock price went down -3.308%.
Which hedge fund is a major shareholder of Novavax?
Hedge funds hold Novavax shares: the largest hedge-fund position in Novavax is 335,323,180 shares, and hedge funds decreased their holdings by 74.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology